# Hydnocarpin **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/hydnocarpin **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-03-20 **Evidence Score:** 2 / 10 **Category:** Compound **Also Known As:** Hydnocarpus wightiana extract, Chaulmoogra flavonolignan, Wight's hydnocarpus compound, Chaulmoogra seed extract, Hydnocarpus seed bioactive, Flavonolignan from Hydnocarpus ## Overview Hydnocarpin is a flavonoid compound that demonstrates potent anti-cancer properties through ROS-mediated apoptosis induction in tumor cells. This bioactive compound exhibits dual mechanisms by triggering cancer cell death while simultaneously modulating immune responses against malignant tissues. ## Health Benefits • Exhibits dual anti-tumor effects on ovarian cancer cells by inducing ROS-mediated apoptosis and modulating immune responses. [1] • Suppresses [T-cell](/ingredients/condition/immune-support) acute lymphoblastic leukemia proliferation via cell cycle arrest and apoptosis. [2] • Demonstrates good [anti-inflammatory](/ingredients/condition/inflammation) and antineoplastic activity in early mouse studies. [6] • Promotes T-cell activation and reduces immune evasion markers in cancer cells. [1] • Triggers ferroptosis in cancer cells, enhancing iron-dependent cell death. [2] ## Mechanism of Action Hydnocarpin exerts its anti-tumor effects primarily through the generation of [reactive oxygen species](/ingredients/condition/antioxidant) (ROS), which triggers [mitochondrial](/ingredients/condition/energy)-mediated apoptosis pathways in cancer cells. The compound induces cell cycle arrest at specific checkpoints, preventing tumor cell proliferation. Additionally, hydnocarpin modulates immune cell function, enhancing the body's natural anti-tumor immune responses through [T-cell](/ingredients/condition/immune-support) regulation. ## Clinical Summary Research on hydnocarpin is primarily limited to in vitro and preclinical studies examining its effects on various cancer cell lines. Studies have demonstrated significant anti-proliferative activity against ovarian cancer cells and [T-cell](/ingredients/condition/immune-support) acute lymphoblastic leukemia through apoptosis induction and cell cycle arrest. Laboratory investigations have also confirmed [anti-inflammatory](/ingredients/condition/inflammation) properties, though specific dosage ranges and bioavailability data remain limited. Human clinical trials are needed to establish therapeutic efficacy and optimal dosing protocols. ## Nutritional Profile Hydnocarpin is a flavonolignan compound (molecular formula C₂₅H₂₂O₁₀, MW ~490 Da) isolated primarily from Hydnocarpus wightiana and members of the Flacourtiaceae family, as well as from milk thistle (Silybum marianum) alongside silybin and silymarin. It is not a dietary macronutrient or micronutrient in the conventional sense; it contains no caloric value, protein, fat, or fiber. As a bioactive flavonolignan, its pharmacological activity is concentration-dependent, with in vitro studies typically employing concentrations in the range of 10–100 µM. Bioavailability is limited due to its polyphenolic structure, which results in low aqueous solubility and susceptibility to hepatic first-pass [metabolism](/ingredients/condition/weight-management) — characteristics common to flavonolignans. Like silybin, it likely undergoes glucuronidation and sulfation in the gut and liver. No established dietary reference intake or tolerable upper limit exists. Its primary relevance is as a phytochemical bioactive rather than a nutritional compound. ## Dosage & Preparation Laboratory studies used concentrations of 7.5–15 µM hydnocarpin D for T-ALL cells and animal studies reported no adverse effects at doses up to 5000 mg/kg. Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions Safety data for hydnocarpin in humans is currently limited due to the lack of clinical trials. As a flavonoid compound, it may interact with medications metabolized by cytochrome P450 enzymes, potentially affecting drug clearance. Individuals taking anticoagulant medications should exercise caution, as flavonoids can influence blood clotting mechanisms. Pregnant and breastfeeding women should avoid hydnocarpin supplementation due to insufficient safety data in these populations. ## Scientific Research There are no human clinical trials of hydnocarpin published in peer-reviewed literature. Existing evidence consists of in vitro and limited in vivo studies, such as those on ovarian cancer and T-ALL cell lines. Further in vivo validation is required before clinical translation. [1] ## Historical & Cultural Context The traditional or historical use of Hydnocarpus wightiana is not documented in the available literature. There is no information about its applications in Ayurvedic or other traditional medicine systems. ## Synergistic Combinations Hydnocarpin pairs well with Silybin (from Silybum marianum), as both are flavonolignans sharing complementary ROS-modulating and apoptosis-inducing pathways, potentially producing additive effects on cancer cell [oxidative stress](/ingredients/condition/antioxidant) while silybin's better-characterized pharmacokinetics may inform co-formulation strategies. Quercetin is a strong complementary partner because its inhibition of P-glycoprotein (P-gp) efflux transporters can counteract multidrug resistance mechanisms — notably, hydnocarpin itself has been identified as a P-gp substrate and inhibitor, and quercetin's parallel P-gp modulation may amplify intracellular retention of both compounds. Piperine (from Piper nigrum, typically at 5–20 mg alongside flavonoid compounds) enhances the bioavailability of poorly soluble polyphenols by inhibiting glucuronidation enzymes (UGT1A) and P-gp, directly addressing hydnocarpin's bioavailability limitations. Additionally, EGCG (epigallocatechin gallate from green tea) complements hydnocarpin's immune-modulatory anti-tumor effects via independent inhibition of [NF-κB](/ingredients/condition/inflammation) and STAT3 signaling pathways, creating a multi-target approach to tumor immune evasion suppression. ## Frequently Asked Questions ### What cancers does hydnocarpin work against? Research shows hydnocarpin demonstrates anti-tumor activity against ovarian cancer cells and T-cell acute lymphoblastic leukemia. The compound induces apoptosis through ROS generation while modulating immune responses against these specific cancer types. ### How does hydnocarpin kill cancer cells? Hydnocarpin kills cancer cells by generating reactive oxygen species (ROS) that trigger mitochondrial-mediated apoptosis pathways. It also induces cell cycle arrest at specific checkpoints, preventing tumor cells from dividing and proliferating. ### Is hydnocarpin safe for daily use? Safety data for daily hydnocarpin use is currently limited as human clinical trials have not been conducted. As a flavonoid, it may interact with certain medications and should be avoided during pregnancy and breastfeeding. ### What is the effective dosage of hydnocarpin? Specific therapeutic dosage ranges for hydnocarpin have not been established in human studies. Current research is limited to laboratory and preclinical investigations, making it impossible to recommend standardized dosing protocols. ### Can hydnocarpin be taken with cancer medications? Hydnocarpin may interact with cancer medications through cytochrome P450 enzyme modulation, potentially affecting drug metabolism. Patients undergoing cancer treatment should consult their oncologist before using hydnocarpin supplements to avoid potential interactions. ### What is the current research status of hydnocarpin as a cancer treatment? Hydnocarpin is in early-stage research, with most evidence coming from in vitro and animal studies demonstrating dual anti-tumor mechanisms in ovarian cancer and T-cell acute lymphoblastic leukemia. While preclinical data shows promising ROS-mediated apoptosis and immune modulation effects, clinical trials in humans have not yet been completed. The ingredient remains investigational and is not FDA-approved as a standalone cancer therapy, though research continues to evaluate its therapeutic potential. ### Who should consider hydnocarpin supplementation based on current research? Currently, hydnocarpin supplementation is primarily of interest to researchers and individuals participating in clinical studies, as human efficacy data is limited. Patients with ovarian cancer or T-cell acute lymphoblastic leukemia should not use hydnocarpin as a replacement for conventional treatment without explicit guidance from their oncologist. Anyone considering hydnocarpin supplementation should consult their healthcare provider, as its safety profile in human populations remains under investigation. ### How does hydnocarpin compare to other natural compounds studied for immune-modulating cancer effects? Hydnocarpin is unique in its dual mechanism of inducing ROS-mediated apoptosis while simultaneously promoting T-cell activation and reducing immune evasion markers, distinguishing it from many single-mechanism compounds. Unlike some natural compounds that primarily enhance apoptosis or inflammation, hydnocarpin appears to address both tumor cell death and anti-tumor immune response in preclinical models. Direct comparative studies between hydnocarpin and other bioactive compounds remain limited, making comprehensive efficacy comparisons premature at this stage of research. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*